Latest news with #MichaelHeinz
Time of India
3 days ago
- Business
- Time of India
German chemicals giant BASF plans IPO of agri solutions biz in India after demerger
1 2 3 Hyderabad: German chemicals giant BASF SE, which is hiving off its agricultural solutions business with plans to list it on the global bourses, plans an initial public offering of its agricultural solutions business in India as well, post demerger from BASF India. This comes as the company is scouting for acquisitions in the small to mid-sized segment in the seeds business as well as biologics, top company officials said on Wednesday. Pointing out that BASF SE is preparing for a potential IPO listing for the agrisolutions business post the second half of 2027, Michael Heinz, member of the board of executive directors of BASF SE, said the legal entity separation is already done, but the call on when to go for the IPO will be taken based on the overall market conditions and other factors. "It could be in the second half of 2027, or the first half of 2028 or later. We will ready the IPO and execute it when circumstances are favourable," Heinz said. Marko Grozdanovic, senior vice-president, Global Strategic Marketing, Agricultural Solutions, BASF SE, said with the additional value they create with the demerger and IPO, the company will be able to make potentially higher investments in India, which is a key market for BASF globally. "We are looking into technologies from our own R&D point of view, but there are also technologies out there where we think about partnerships and acquisitions in the area of seeds, both vegetable seeds and row crops, or in the area of biologicals where India could play a role for future investments," Grozdanovic said. Talking about the Indian agri solutions business IPO, BASF India Ltd managing director Alexander Gerding said the demerger will take 18–24 months, and once it is completed, they will be listing the new agri solutions company on the Indian stock exchanges as part of efforts to unlock value for shareholders.
Forbes
10-04-2025
- Health
- Forbes
Therabot Humanizes AI Help, Recasts Tech Strategy
Dartmouth researchers successfully piloted AI-powered therapy. Groundbreaking Dartmouth research could reshape mental health care with an AI-powered therapy chatbot that wins patient trust and delivers measurable clinical gains. The implications reach far beyond the clinical couch and deep into corporate c-suites. Therabot's trial treated over 100 participants diagnosed with depression, anxiety or eating disorders. After eight weeks, the symptom reduction results published in the New England Journal of Medicine were striking. "Our results are comparable to what we would see for people with access to gold-standard cognitive therapy with outpatient providers," Dartmouth Geisel School of Medicine professor Nick Jacobson highlighted. For businesses struggling with employee mental health concerns and skyrocketing healthcare costs, AI solutions like Therabot could represent a scalable intervention that meets high standards. It also recasts workplace debates about how widely AI can help. What makes Therabot particularly notable is its success in a field long considered "AI-proof" due to the presumed necessity of personal empathy and connection. If AI can forge therapeutic relationships comparable to those with human providers, few professional domains can confidently claim immunity from similar disruption. Participants reported genuine, trusted connections with Therabot. Users frequently initiated conversations with the AI beyond prompted interactions, with usage spikes seen during vulnerable times such as the middle of the night. This unexpected development suggests AI systems might fill social and emotional support roles that extend beyond therapy to outdated approaches to legacy business functions such as sales and marketing, customer service, hiring and training. Unlike location-bound counseling, AI therapy can intervene at critical moments. "It was available around the clock for challenges that arose in daily life and could walk users through strategies to handle them in real time," says co-author Dartmouth postdoctoral fellow Michael Heinz. For employers, this access could reduce absenteeism. That's elusive process efficiency that simultaneously delivers heightened effectiveness. Therabot shows AI's capability to spur innovation and humans' capacity to thwart it. Since the pioneering mid-1960s release of Joseph Weizenbaum's ELIZA, the risks of tech-based therapy have been well documented and exhaustively debated. Therabot models responsible AI development in high-stakes domains. "There are a lot of folks rushing into this space since the release of ChatGPT and it's easy to put out a proof of concept that looks great at first glance, but the safety and efficacy is not well established," Jacobson notes. "This is one of those cases where diligent oversight is needed and providing that really sets us apart." Therabot's extensive input from mental health leaders shows that slow, methodical development yields better trusted products. AI's success in 'uniquely human' realms signals more disruption risk for legacy jobs. Many employers may not even sense the boundless potential or looming jeopardy. To date, AI has conquered time by speeding many highly-structured work tasks. Now, leaders must ask how it can tackle the high-touch, ill-structured activities. Those tech strategy solutions start with credible leadership, curious culture and capable talent. In turn, ten questions assess AI attitudes, awareness, ambition, aspiration – and odds: The (non)answers tell all. The question isn't whether AI will transform business, but how quickly. The open question is who will be the change architects or casualties. Bot therapy, anyone?
